Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

orbed over time by the vascular tissue as part of the body's normal processes. If clinical results are positive, bioabsorbable drug eluting stents could eventually offer an alternative to the metallic drug eluting stents available to patients today.

About XIENCE V

Abbott's market-leading XIENCE V drug eluting stent was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at www.xiencev.com.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  El Camino Hospital, a leader in the ... the Leaf Patient Monitoring system to help prevent hospital-acquired ... patients susceptible to bed sores. The decision ... of the system, which showed dramatic improvement in compliance ... is the one of the most effect ways to ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that ... research imaging system market will be significantly driven ... combining computed tomography and magnetic resonance imaging with ... from the need for higher-quality imaging to satisfy ... will spur preclinical imaging system sales. ...
(Date:7/30/2014)... July 30, 2014 Stryker brand ambassadors Fred Funk ... the 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products ... Starting Friday, August 1 st through Sunday, August 3 rd ... an on-site joint health destination located in the Pioneer Press Expo ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3Growing Popularity of Multimodality Imaging Will Drive the Preclinical Animal Research Imaging System Market 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5
... ESRX ), one of the largest pharmacy benefit ... release its third quarter earnings on Tuesday, October 25, 2011 ... call to discuss third quarter results on Wednesday, October 26, ... This call is being webcast and can be ...
... YORK, Oct. 17, 2011 Levi & Korsinsky is investigating ... the "Company") (NASDAQ: ANDS ) for possible breaches ... connection with the sale of the Company to Roche Holding ... receive $3.70 in cash per share of Anadys stock they ...
Cached Medicine Technology:The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Anadys Pharmaceuticals Inc. in Connection with the Sale of the Company to Roche Holding AG 2
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... According to the market research ... by Technology (ICS, MES, ERP, ITS), Field Devices, ... Application (Process, Discrete) - Global Forecast & Analysis ... Mexican market is expected to reach $6.99 Billion ... Browse 70 market data Tables and 96 Figures ...
(Date:7/30/2014)... Everyone knows that the internet is the absolute center of ... for something to buy, trying to reconnect with friends, or ... much always going to be the go to resource. That ... happy to announce the launch of their brand new website ... Whether a person wants to know what the Sierra Dental ...
(Date:7/30/2014)... July 30, 2014 Shabaikai is an ... forests of the Pomo Indians located on the shores ... the river Shabaikai, meaning ‘crooked snake’. Clarkson takes the ... and the violence of prohibition and organized crime, providing ... River. Here, the most powerful men in the world ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 “North ... key market data on the North America Contrast Media ... US dollars, and volume (in units) and average price ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and ... (or contrast agent) is a substance used to enhance ...
Breaking Medicine News(10 mins):Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4
... academics have been awarded funds from a huge European ... of individual people which could lead to everyone ... genetic and physiological make-up. Under the system, doctors ... of an individual patient,s health needs and medical history ...
... Steven Reinberg HealthDay Reporter , SUNDAY, July 24 ... new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result ... and stroke, a new study finds. A trial evaluating ... severe bleeding among those taking Eliquis (apixaban) became apparent. ...
... July 23 (HealthDay News) -- Swimming may be easy on ... The most common injury among those who practice the ... percent of competitive swimmers, said Dr. Scott A. Rodeo, co-chief ... Special Surgery in New York City, who recently spoke at ...
... News) -- The ability of dolphins to resist infection and ... the treatment of human wounds, a researcher suggests. , ... documented," Dr. Michael Zasloff, adjunct professor at Georgetown University Medical ... news release. "How does the dolphin not bleed ...
... study by researchers at Drexel University,s School of Public Health ... gateway to the use of injected drugs such as heroin, ... drugs. The study, published in the International Journal of ... initiation into the misuse of opioid drugs. Common factors identified ...
... Amanda Gardner HealthDay Reporter , THURSDAY, July 21 ... Internet on their smartphones tend to hold the devices closer ... to work harder than usual, new research shows. This ... smartphones -- could put added strain on people who already ...
Cached Medicine News:Health News:Computer program could 'revolutionize the world's health care' 2Health News:Computer program could 'revolutionize the world's health care' 3Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3Health News:Common Swimming Injuries Often Avoidable 2Health News:Dolphins' Superior Ability to Heal May Help Humans 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 3Health News:Smartphones May Be Taxing Your Eyes 2Health News:Smartphones May Be Taxing Your Eyes 3
... Medication Delivery., ,Designed for adolescent ... incorporates an additional lumen and injection ... the cuff., ,SHERIDAN offers three ... CO2 monitoring, pressure monitoring or medication ...
... For Laryngotracheal Instillation of Topical Anesthetic, ... populations, this cuffed tube incorporates an ... spray application of topical anesthetic above ... offers three endotracheal tubes designs which ...
... ,Designed for neonatal and pediatric patient ... monitoring lumen within the wall of the ... Luer lock connector bonded to lumen line ... monitoring or syringe irrigation of medication., ...
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
Medicine Products: